Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses
Primary Purpose
Myopia
Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Delefilcon A contact lenses (DAILIES TOTAL1®)
Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)
Sponsored by
About this trial
This is an interventional treatment trial for Myopia focused on measuring contact lenses, myopia
Eligibility Criteria
Inclusion Criteria:
- Sign written Informed Consent Document and HIPAA form.
- Be current weekly/monthly replacement contact lens wearer.
- Be willing to not sleep in contact lenses during the study period.
- Require vision correction in both eyes, with a contact lens prescription in protocol-specified power range.
- Have best corrected visual acuity of at least 20/25 in each eye.
- Be willing to wear study lenses for at least 8 hours/day and at least 5 days/week.
- Use re-wetting drops less than once per day and be willing to discontinue use of rewetting drops while wearing the study contact lenses.
- Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
- Be a neophyte or current wearer of daily disposable lenses.
- Require monovision correction or use multifocal contact lenses.
- Have any systemic or ocular disease or disorder, complicating factor, or structural abnormality that would negatively affect the conduct or outcome of the study.
- Have a history of ocular surgery/trauma within the last 6 months.
- Use topical ocular or systemic antibiotics within 7 days of enrollment.
- Use topical ocular or systemic corticosteroids within 14 days of enrollment, continuing throughout the study.
- Have participated in any other ophthalmic drug or device clinical trial within 30 days of enrollment.
- Have habitually worn contact lenses on an extended wear basis (sleeping in habitual contact lenses for at least 2 nights per week) in the last 3 months prior to enrollment.
- Use re-wetting drops once or more per day.
- Other protocol-defined exclusion criteria may apply.
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm Type
Other
Other
Arm Label
Delefilcon A, then narafilcon B
Narafilcon B, then delefilcon A
Arm Description
Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
Outcomes
Primary Outcome Measures
Overall Comfort
Overall comfort was interpreted by the participant and recorded on a questionnaire as a single, retrospective evaluation of 8 days of wear. Overall comfort was evaluated binocularly and rated on a 10-point scale, with 1 being poor and 10 being excellent. Both eyes contributed to the mean.
Secondary Outcome Measures
Overall Quality of Vision
Overall quality of vision was interpreted by the participant and recorded on a questionnaire as a single, retrospective evaluation of 8 days of wear. Overall quality of vision was evaluated binocularly and rated on a 10-point scale, with 1 being poor and 10 being excellent. Both eyes contributed to the mean.
End of Day Comfort
End of day comfort was interpreted by the participant and recorded on a questionnaire as a single, retrospective evaluation of 8 days of wear. End of day comfort was evaluated binocularly and rated on a 10-point scale, with 1 being poor and 10 being excellent. Both eyes contributed to the mean.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01634659
Brief Title
Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses
Official Title
Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses
Study Type
Interventional
2. Study Status
Record Verification Date
November 2013
Overall Recruitment Status
Completed
Study Start Date
July 2012 (undefined)
Primary Completion Date
September 2012 (Actual)
Study Completion Date
September 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alcon Research
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The purpose of this study was to compare the subjective performance of DAILIES TOTAL1® daily disposable contact lenses to that of 1-DAY ACUVUE® TruEye® daily disposable contact lenses.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Myopia
Keywords
contact lenses, myopia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Masking
Participant
Allocation
Randomized
Enrollment
330 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Delefilcon A, then narafilcon B
Arm Type
Other
Arm Description
Delefilcon A contact lenses (DAILIES TOTAL1®) worn first, followed by narafilcon B contact lenses (1-DAY ACUVUE® TruEye®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
Arm Title
Narafilcon B, then delefilcon A
Arm Type
Other
Arm Description
Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®) worn first, followed by delefilcon A contact lenses (DAILIES TOTAL1®). Each product was worn bilaterally (ie, in both eyes) in a daily wear, daily disposable mode for 8 days.
Intervention Type
Device
Intervention Name(s)
Delefilcon A contact lenses (DAILIES TOTAL1®)
Intervention Description
Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
Intervention Type
Device
Intervention Name(s)
Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)
Intervention Description
Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
Primary Outcome Measure Information:
Title
Overall Comfort
Description
Overall comfort was interpreted by the participant and recorded on a questionnaire as a single, retrospective evaluation of 8 days of wear. Overall comfort was evaluated binocularly and rated on a 10-point scale, with 1 being poor and 10 being excellent. Both eyes contributed to the mean.
Time Frame
Day 8
Secondary Outcome Measure Information:
Title
Overall Quality of Vision
Description
Overall quality of vision was interpreted by the participant and recorded on a questionnaire as a single, retrospective evaluation of 8 days of wear. Overall quality of vision was evaluated binocularly and rated on a 10-point scale, with 1 being poor and 10 being excellent. Both eyes contributed to the mean.
Time Frame
Day 8
Title
End of Day Comfort
Description
End of day comfort was interpreted by the participant and recorded on a questionnaire as a single, retrospective evaluation of 8 days of wear. End of day comfort was evaluated binocularly and rated on a 10-point scale, with 1 being poor and 10 being excellent. Both eyes contributed to the mean.
Time Frame
Day 8
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Sign written Informed Consent Document and HIPAA form.
Be current weekly/monthly replacement contact lens wearer.
Be willing to not sleep in contact lenses during the study period.
Require vision correction in both eyes, with a contact lens prescription in protocol-specified power range.
Have best corrected visual acuity of at least 20/25 in each eye.
Be willing to wear study lenses for at least 8 hours/day and at least 5 days/week.
Use re-wetting drops less than once per day and be willing to discontinue use of rewetting drops while wearing the study contact lenses.
Other protocol-specified inclusion criteria may apply.
Exclusion Criteria:
Be a neophyte or current wearer of daily disposable lenses.
Require monovision correction or use multifocal contact lenses.
Have any systemic or ocular disease or disorder, complicating factor, or structural abnormality that would negatively affect the conduct or outcome of the study.
Have a history of ocular surgery/trauma within the last 6 months.
Use topical ocular or systemic antibiotics within 7 days of enrollment.
Use topical ocular or systemic corticosteroids within 14 days of enrollment, continuing throughout the study.
Have participated in any other ophthalmic drug or device clinical trial within 30 days of enrollment.
Have habitually worn contact lenses on an extended wear basis (sleeping in habitual contact lenses for at least 2 nights per week) in the last 3 months prior to enrollment.
Use re-wetting drops once or more per day.
Other protocol-defined exclusion criteria may apply.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jami Kern, MBA, PhD
Organizational Affiliation
Alcon Research
Official's Role
Study Director
12. IPD Sharing Statement
Learn more about this trial
Clinical Evaluation of Two Daily Disposable Silicone Hydrogel Contact Lenses
We'll reach out to this number within 24 hrs